PHOSLYRA SIDE EFFECTS
No clinical trials have been performed with PHOSLYRA in the intended population. Because the dose and active ingredients of PHOSLYRA are equivalent to that of the calcium acetate gelcaps or tablets, the scope of the adverse reactions is anticipated to be similar.
Hypercalcemia is discussed elsewhere.
Clinical Trial Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
In clinical studies, calcium acetate has been generally well tolerated.
The solid dose formulation of calcium acetate was studied in a 3-month, open-label, non-randomized study of 98 enrolled ESRD hemodialysis patients and in a two week double-blind, placebo-controlled, cross-over study with 69 enrolled ESRD hemodialysis patients. Adverse reactions ( > 2% on treatment) from these trials are presented in Table 1.
Table 1: Adverse Reactions in Patients with End-Stage Renal Disease Undergoing Hemodialysis
|Preferred Term||Total adverse reactions reported for calcium acetate
|3-mo, open-label study of calcium acetate
|Double-blind, placebo-controlled, cross-over study of calcium acetate
|Nausea||6 (3.6)||6 (6.1)||0 (0.0)||0 (0.0)|
|Vomiting||4 (2.4)||4 (4.1)||0 (0.0)||0 (0.0)|
|Hypercalcemia||21 (12.6)||16 (16.3)||5 (7.2)||0 (0.0)|
Calcium acetate oral solution was studied in a randomized, controlled, 3-arm, open label, crossover, single-dose study comparing calcium acetate oral solution to a solid formulation in healthy volunteers on a controlled diet. Of the observed drug-related adverse reactions, diarrhea (5/38, 13.2%) was more common with the oral solution.
Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency or to establish a causal relationship to drug exposure.
The following additional adverse reactions have been identified during post-approval of calcium acetate: dizziness, edema, and weakness.
SRC: NLM .